SCHEMBL268833

SCHEMBL268833

CCN(CC)Cc1cccc(C(=O)Nc2sc(CN3CCCCC3)c(C)c2C(=O)N/N=C/c2ccc(OC)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HTT P42858 1/20 0.45
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
ACHE P22303 1/20 0.42
SLC34A2 O95436 7/20 0.42
ENPP2 Q13822 1/20 0.41
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL268834 1.00 MAPT (0.45) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL266043 0.85 SLC34A2 (0.60) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL266044 0.85 SLC34A2 (0.60) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL274372 0.85 SLC34A2 (0.60) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL268309 0.83 RAB9A (0.42) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL267793 0.81 MEN1 (0.49) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL267806 0.79 MAPT (0.44) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL267805 0.79 MAPT (0.44) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL267672 0.79 TP53 (0.54) MAPTSMN1; SMN2SLC34A2LMNATP53
SCHEMBL267671 0.79 TP53 (0.54) MAPTSMN1; SMN2SLC34A2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885SMN1; SMN2 3975/4885KDM4E 4468/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885SMN1; SMN2 4253/4885KDM4E 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.